Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Have Been Previously Exposed to TNF Inhibitors

NCT02100696 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02100696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02100696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Have Been Previously Exposed to TNF Inhibitors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
May 21, 2014
Completion date
April 16, 2020
Enrollment
609 (actual)
Sites
184

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis